Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2569–2592 of 21,035 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Immune System Disorders Clear all

Conditions: Multiple Myeloma
Interventions: Teclistamab, Mezigdomide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Cancer
Interventions: entinostat; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 3
States / cities: Bethesda, Maryland

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Precancerous/Nonmalignant Condition, Small Intestine Cancer
Interventions: anti-thymocyte globulin, graft-versus-tumor induction therapy, cyclophosphamide, fludarabine phosphate, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Up to 70 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Melanoma
Interventions: Pimonidazole; Drug
Lead sponsor: Yana Najjar; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Myositis, Dermatomyositis, Polymyositis, Juvenile Dermatomyositis, Juvenile Polymyositis
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 2 Years to 100 Years
Enrollment: 580 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 8
States / cities: Miami, Florida • Baltimore, Maryland • Bethesda, Maryland + 5 more

Conditions: Allergic Conjunctivitis
Interventions: Olopatadine hydrochloride ophthalmic solution, 0.2%; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Interventions: Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography, External Beam Radiation Therapy, Leukapheresis, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Biological · Radiation
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Cervical Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Metastatic Castration Resistant Prostate Cancer, Non-hodgkin Lymphoma
Interventions: CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab; Drug
Lead sponsor: Corvus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 22
States / cities: Tucson, Arizona • Duarte, California • San Francisco, California + 18 more

Conditions: Rheumatoid Arthritis
Interventions: fish oil, borage seed oil, combination fish oil and borage seed oil; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 85 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 13
States / cities: Birmingham, Alabama • Trumbull, Connecticut • Boca Raton, Florida + 9 more

Conditions: Persistent Asthma
Interventions: Beclomethasone dipropionate breath-actuated inhaler, Placebo breath-actuated inhaler, albuterol/salbutamol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 47
States / cities: Huntington Beach, California • Mission Viejo, California • Orange, California + 41 more

Conditions: Influenza Like Illness, Asthma, Group A Streptococcal Infection, Pertussis
Interventions: What's Going Around tool, Control; Other
Lead sponsor: Endeavor Health; Other
Eligibility: Not listed
Enrollment: 206,703 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Cognitive Disorders, HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 25
States / cities: Menlo Park, California • San Diego, California • San Francisco, California + 17 more

Conditions: Lymphoma, Non-Hodgkin, Lymphoma, Low-Grade
Interventions: ibritumomab tiuxetan (Zevalin®); Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 8
States / cities: Loma Linda, California • Oceanside, California • Fairfield, Connecticut + 5 more

Conditions: Activated PI3Kdelta Syndrome (APDS); PASLI Disease
Interventions: CDZ173; Drug
Lead sponsor: Pharming Technologies B.V.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases, Skin Diseases, Genetic, Genetic Diseases, Inborn, Skin Diseases, Eczematous, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases
Interventions: PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab, Oral Placebo, Injectable Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 838 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 60
States / cities: Birmingham, Alabama • Huntington Beach, California • Laguna Hills, California + 52 more

Conditions: Hepatitis B, HIV Infections
Interventions: Selgantolimod, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: San Diego, California • Atlanta, Georgia • New York, New York + 4 more

Conditions: Multiple Myeloma
Interventions: Psychoeducational intervention, behavioral intervention, counseling intervention, educational intervention, telephone-based intervention, questionnaire administration, quality-of-life assessment; Other · Behavioral
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: IGA Glomerulonephritis
Interventions: Not listed
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 0 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Non-Hodgkin Lymphoma
Interventions: Chemotherapy and Radioimmunotherapy; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pneumococcal Vaccine, Esophageal Cancer, Lymphopenia, Chemoradiation
Interventions: Pneumonia vaccine; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infection
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 12 Years to 24 Years
Enrollment: 16,706 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2010
U.S. locations: 14
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 11 more

Conditions: Fatigue, Rheumatoid Arthritis
Interventions: Virtual Reality Meditation; Device
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Type 1 Diabetes, Eating Disorders
Interventions: Diabetes Body Project, Educational Group; Behavioral
Lead sponsor: Oslo University Hospital; Other
Eligibility: 14 Years to 35 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Stanford, California • Boston, Massachusetts

Conditions: HIV Infections
Interventions: HealthMindr App, Control App; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 34 Years · Male only
Enrollment: 658 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Jackson, Mississippi

Search by objective public record fields.

A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Non-Ablative Allo HSCT For Hematologic Malignancies or SAA

Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma

Environmental Risk Factors for the Anti-synthetase Syndrome

Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients

Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

Treatment of Rheumatoid Arthritis With Marine and Botanical Oils

A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma

How Does the Clinical Tool 'What's Going Around' Affect Clinical Practice

HIV Levels in Cerebrospinal Fluid and Brain Function in Patients Receiving Anti-HIV Drugs

Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma

Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV

Psychoeducational and Behavioral Strategies in Reducing Distress and Anxiety in Patients With Multiple Myeloma and Their Family Caregivers

Study of Genetic Anomalies of Complement Related Proteins in Patients With IgA Glomerulonephritis

Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma

Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation

Connect to Protect Partnerships for Youth Prevention Interventions: Phase II

Virtual Reality Meditation for Fatigue

Multi-Site Eating Disorder Prevention Program for Type 1 Diabetes

HealthMindr App to Increase Pre-exposure Prophylaxis (PrEP) Uptake and Retention Among Men Who Have Sex With Men (MSM)